For Cisplatin and lupeol, known to synergistically inhibit hepatocellular carcinoma through the PI3K‐Akt pathway,[74] our analysis showed strong enrichment in this pathway (P‐value = 7.17 × 10−78). Here, AKT1 is linked to hepatocellular carcinoma.